



## News Release

### **Suven Revenue growth at 13.42%; PAT up by 29.15% for the half year ended Sept, 2016**

**HYDERABAD, INDIA (24 Nov' 2016)** – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2016. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 24th Nov' 2016 at Pashamylaram (Unit 3), Medak Dist, Telangana.

#### **Financial Highlights for the Half year ended September' 2016:**

Growth in revenue INR 2600 Mn vs Rs 2293 Mn - up by 13.42%  
Growth in PAT INR 589 Mn vs. Rs 456 Mn - up by 29.15%  
Growth in EBIDTA INR 916 Mn vs. Rs 679 Mn - up by 34.88%

#### **Financial Highlights for the 2nd Quarter ended September' 2016 (QoQ):**

Growth in revenue INR 1223 Mn vs Rs 1377 Mn - down by 11.20%  
Growth in PAT INR 264 Mn vs. Rs 325 Mn - down by 18.54%  
Growth in EBIDTA INR 436 Mn vs. Rs 479 Mn - down by 8.96%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 293 Mn (11.28% on revenue) for the half year ended Sept' 2016.

*For more information on Suven please visit our Web site at <http://www.suven.com>*

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***